<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742297</url>
  </required_header>
  <id_info>
    <org_study_id>GEM2017FIT</org_study_id>
    <nct_id>NCT03742297</nct_id>
  </id_info>
  <brief_title>Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years</brief_title>
  <official_title>Induction Therapy With Bortezomib-melphalan and Prednisone (VMP) Followed by Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab, 18 Cycles, Followed by Consolidation and Maintenance Therapy With Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a randomized, controlled, open-label, assessor blind, multicenter&#xD;
      superiority trial with three parallel groups, and primary endpoint of immunophenotypic&#xD;
      complete responses at 18 months after randomization. Block randomization will be performed&#xD;
      with a 1:1:1 allocation ratio.&#xD;
&#xD;
      Patients will be randomized up front to 3 arms. Patients will receive &quot;standard&quot; PETHEMA arm&#xD;
      for fit elderly VMP x 9 + Rd x 9 (arm 1, control arm), a KRd regimen (arm 2a) (18 cycles) or&#xD;
      a Carfilzomib-lenalidomida-dexametasona regimen combined with DARATUMUMAB (arm 2b) (18&#xD;
      cycles).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 18 cycles, patients not having received daratumumab before (arm 1 and 2a), will receive&#xD;
      consolidation with 4 cycles of Lenalidomida-dexamethasone at low dose-DARATUMUMAB.&#xD;
&#xD;
      At this point (after 22 months on treatment for the VMP-Rd and KRd arm and after 18 months of&#xD;
      the Carfilzomib-lenalidomida-dexametasona-DARATUMUMAB arm) patients will be stratified&#xD;
      according MRD status by flow and in both MRD- and MRD+ groups, patients will be randomized&#xD;
      with a 1:1 allocation ratio to:&#xD;
&#xD;
        1. no further treatment or&#xD;
&#xD;
        2. continuous treatment with DARATUMUMAB-R (daratumumab plus lenalidomide up to 2 years and&#xD;
           then lenalidomide continuous until progression).&#xD;
&#xD;
      Patients on no maintenance that show biological relapse will be rechallenged with&#xD;
      DARATUMUMAB-R.&#xD;
&#xD;
      The translational part will be very robust with dysplasia monitoring (especially relevant for&#xD;
      the Bortezomib-melfalán-prednisona + Lenalidomida-dexamethasone at low dose arm), clonal&#xD;
      evolution/resistance follow up and immune reconstitution longitudinal follow up alongside&#xD;
      with MRD status (at diagnosis, 9 months, 18 months, 22 months and treatment discontinuation).&#xD;
&#xD;
      The trial is designed as a two-stage study (induction, followed by consolidation and&#xD;
      maintenance). The first stage is confirmatory and addresses the primary efficacy objective.&#xD;
      The second stage is exploratory and addresses the secondary efficacy and safety objectives.&#xD;
&#xD;
      In the first stage, investigators will compare an optimized standard induction Bortezomib,&#xD;
      talidomida and prednisone followed by Rd (18 cycles) versus KRd, that will be tested in this&#xD;
      trial with or without daratumumab x 18 cycles. The main objective in this stage will be to&#xD;
      compare the immunophenotypic complete response rate assessed by next generation flow at the&#xD;
      end of induction.&#xD;
&#xD;
      The second stage is exploratory and includes the consolidation and maintenance phases. In&#xD;
      this second stage, the main objectives are:&#xD;
&#xD;
        1. To compare the above mentioned induction strategies in terms of PFS at the end of the&#xD;
           different treatment phases (induction, consolidation and maintenance).&#xD;
&#xD;
        2. To investigate the capacity of consolidation with daratumumab-lenalidomide to reduce MRD&#xD;
           levels in patients treated in the control arm as well as those that received KRd without&#xD;
           daratumumab. In addition we will explore if this short consolidation can abrogate the&#xD;
           potential benefit of a prolonged induction with KRd+daratumumab&#xD;
&#xD;
        3. To explore the value of maintenance therapy according to MRD status (positive or&#xD;
           negative) to prolong PFS (after a second randomization to receive or not maintenance&#xD;
           therapy with lenalidomide and daratumumab) In order to prevent a potential treatment&#xD;
           deficiency for patients randomized to &quot;no-maintenance&quot; in both MRD+ and MRD- subgroups,&#xD;
           they will be offered to be re-challenged with lenalidomide-daratumumab as soon as they&#xD;
           have a biological progression and have been censored for PFS. Moreover, if 30% of the&#xD;
           patients randomized to &quot;no-maintenance&quot; relapse or progress during the first year, the&#xD;
           protocol will be amended so that all patients receive maintenance therapy.&#xD;
&#xD;
      Investigators consider that the here proposed multidrug sequential &quot;intensive&quot; approach&#xD;
      designed to obtain the best possible and most durable response, assessed through the kinetics&#xD;
      of MRD clearance, may have an impact in establishing future clinical practice in fit elderly&#xD;
      patients. Moreover, in addition to the MRD analysis (based on next generation flow (NGF), NGS&#xD;
      and CT-PET) comprehensive biological investigations, including immunoprofile, clonal&#xD;
      selection, analysis of dysplastic features and circulating tumor cells, are planned in order&#xD;
      to better understand the relationship between patients outcome and myeloma biology.&#xD;
&#xD;
      The overall treatment plan has been designed for NDMM patients not candidates to SCT&#xD;
      strategies but fit enough to tolerate a relatively intensive therapeutic strategy. According&#xD;
      to the International Myeloma Working Group guidelines as well as the results obtained in our&#xD;
      GEM2010 trial for elderly patients, we have decided to restrict this trial to fit elderly&#xD;
      patients aged between 65 and 80 years because in our experience patients older than 80 years&#xD;
      usually intensive treatments are poorly tolerated [1].&#xD;
&#xD;
      Investigators will evaluate the frailty using a comprehensive health status assessment scale&#xD;
      (Geriatric Assessment in Hematology, GAH scale, annex 11), already validated in patients with&#xD;
      hematological diseases and preliminary results in multiple myeloma patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">October 22, 2031</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of numbers of compleat responses</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of immunophenotypic complete responses at 18 months, of the standard treatment in Spain for newly diagnosed multiple myeloma patients not candidates to stem cell transplantation,</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 &amp; 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 &amp; 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 &amp; 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 &amp; 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 &amp; 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 &amp; 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide.</intervention_name>
    <description>Lenalidomide</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib</description>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone</description>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan</description>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed multiple myeloma patients who require start active treatment according&#xD;
             to the IMWG published in 2014&#xD;
&#xD;
          -  Age between 65 and 80 years, both included&#xD;
&#xD;
          -  Fit patient assessed using the comprehensive health status assessment scale (Geriatric&#xD;
             Assessment in Hematology, GAH scale, annex 11) (0-94 points GAH scale). Patients with&#xD;
             a punctuation ≤42 will be included.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients must have measurable disease, defined as follows:&#xD;
&#xD;
        For secretory Multiple Myeloma, measurable disease is defined as the presence of&#xD;
        quantifiable monoclonal component, ≥ 0.5 g/dL or, the urine light chains excretion is 200&#xD;
        mg/24h or higher.&#xD;
&#xD;
        For poor secretory or non secretory Multiple Myeloma, the level of the affected serum free&#xD;
        light chain must be ≥ 10 mg/dL (≥ 100 mg/L, with an abnormal free light-chain ratio)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status ≤2&#xD;
&#xD;
          -  Life expectancy more than 3 months&#xD;
&#xD;
          -  Adequate organ functions:&#xD;
&#xD;
        Platelet count ≥ 50000/mm3, hemoglobin ≥ 8 g/dl and absolute neutrophil count ≥ 1000/mm3.&#xD;
        Lower values are allowed only if they are due to BM infiltration.&#xD;
&#xD;
        Aspartate Transaminase (AST) and Alanine Transaminase (ALT) ≤ 2.5 x Upper Limit of Normal.&#xD;
&#xD;
        Total bilirubin: ≤2 x Upper Limit of Normal. Serum creatinine ≤ 2 mg/dl. Calcium ≤14mg/dl&#xD;
        or corrected serum calcium ≤14mg/dl in patients whose albumin level is out of range Left&#xD;
        ventricle ejection fraction ≥ 40%&#xD;
&#xD;
          -  At the discretion of the investigator patient must be able to adhere to all study&#xD;
             requirements.&#xD;
&#xD;
          -  Male patients that receives lenalidomide should commit to use of a condom while taking&#xD;
             the study drug every time he has sexual contact with a pregnant female of female of&#xD;
             childbearing potential even if he has undergone a successful vasectomy; or practice&#xD;
             complete abstinence (when this is the preferred and usual lifestyle of the subject);&#xD;
             including during periods of dose interruptions and for at least 30 days after&#xD;
             treatment completion. Also males under lenalidomide should commit not to donate semen&#xD;
             or sperm during study drug treatment, including during periods of dose interruptions,&#xD;
             and for at least 90 days after treatment completion.&#xD;
&#xD;
        NOTE: Given the age of patients to be included on this Clinical Trial (between 65 and 80&#xD;
        years, both included), there is no possibility of Females of Childbearing Potential (FCBP),&#xD;
        therefore the Pregnancy Prevention Program (annex 12) has been modified accordingly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients older than 81 years or younger than 65&#xD;
&#xD;
          -  Patients that do not qualify for fit according to the GAH scale (annex 11) (&gt;43 points&#xD;
             GAH scale)&#xD;
&#xD;
          -  Patients who have previously received treatment for multiple myeloma, except for&#xD;
             steroid pulses in case of emergency, the administration of bisphosphonates or&#xD;
             antialgesic radiotherapy or due to the presence of plasmacytomas requiring some&#xD;
             emergency.&#xD;
&#xD;
          -  Men who does not agree to use a condom every time he has sexual contact with a&#xD;
             pregnant female or female of childbearing potential, even if he has undergone a&#xD;
             successful vasectomy, or men who does not agree to practice complete abstinence (if&#xD;
             this is the preferred and usual lifestyle of the subject).&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;40% Prior history of malignancies, other than&#xD;
             multiple myeloma (except for basal or squamous cell carcinoma of the skin, carcinoma&#xD;
             in situ of the cervix or the breast), unless the patient has been free of the disease&#xD;
             for ≥ 5 years.&#xD;
&#xD;
          -  Other relevant diseases or adverse clinical conditions:&#xD;
&#xD;
        Myocardial infarction within the 6 months prior to inclusion in the clinical trial A NYHA&#xD;
        functional class III-IV, heart failure, uncontrolled angina, uncontrolled ventricular&#xD;
        arrhythmia or acute ischemia detected electrocardiographically or conduction system&#xD;
        anomalies.&#xD;
&#xD;
        History of significant neurological or psychiatric disorders. Active infection. Significant&#xD;
        non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).&#xD;
&#xD;
        Poorly controlled arterial hypertension. Any serious medical condition or psychiatric&#xD;
        illness that would interfere in understanding of the informed consent form.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive or&#xD;
             active hepatitis C infection&#xD;
&#xD;
          -  Limitation of the patient's ability to comply with the treatment or follow-up&#xD;
             protocol.&#xD;
&#xD;
          -  Uncontrolled endocrine diseases (i.e. diabetes mellitus, hypothyroidism or&#xD;
             hyperthyroidism) (i.e. requiring relevant changes in medication within the last month,&#xD;
             or hospital admission within the last 3 months).&#xD;
&#xD;
          -  Patients having a peripheral neuropathy ≥ Grade 2 within the 14 days prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Known hypersensibility to any of the study drugs or their excipients.&#xD;
&#xD;
          -  Patients treated with any investigational drug during the previous 30 days.&#xD;
&#xD;
          -  Patients with acute diffuse infiltrative pulmonary disease and/or pericardial disease.&#xD;
&#xD;
          -  Patients who are unable or unwilling to undergo antithrombotic therapy.&#xD;
&#xD;
          -  Patients with severe chronic obstructive pulmonary disease (COPD) or asthma with&#xD;
             forced expiratory volume in the first minute (FEVI) less than 50%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús F San Miguel</last_name>
    <role>Study Chair</role>
    <affiliation>Clínica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Blade, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Jose Lahuerta, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M Victoria Mateos, Dr</last_name>
    <phone>+34923 29 11 00</phone>
    <email>mvmateos@usal.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana María Vale López, Dr</last_name>
      <phone>981 176654</phone>
      <email>Ana.MA.Vale.Lopez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángela Martínez Hellín, Dr</last_name>
      <phone>976 597799</phone>
      <email>angelamartinezhellin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascual Fernández Abellán, Dr</last_name>
      <phone>965 140268</phone>
      <email>fernandez_pas@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol (ICO Badalona)</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Oriol Rocafiguera</last_name>
      <phone>93 4978987</phone>
      <email>aoriol@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rosiñol, Dr</last_name>
      <phone>93 2275400</phone>
      <email>LROSINOL@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Granell Gorrochategui, Dr</last_name>
      <phone>93 5565647</phone>
      <email>MGranell@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Gironella Mesa, Dr</last_name>
      <phone>93 2746100</phone>
      <email>mgironel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L´Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sureda Balari, Dr</last_name>
      <phone>93 2607750</phone>
      <email>asureda@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Amutio Díez, Dr</last_name>
      <phone>946 006320</phone>
      <email>mariaelena.amutiodiez@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Cáceres</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Cabrera Silva, Dr</last_name>
      <phone>927 256200</phone>
      <email>ccabrerasilva1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Álvarez Rivas, Dr</last_name>
      <phone>957 010309</phone>
      <email>mangel.alvarez.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Esther González García, Dr</last_name>
      <phone>985 185000</phone>
      <email>esthergongar@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta (ICO Girona)</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda González Montes, Dr</last_name>
      <phone>972 225833</phone>
      <email>ygonzalez@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Ríos Tamayo</last_name>
      <phone>958 020000</phone>
      <email>rafael.rios.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastián Garzón López, Dr</last_name>
      <phone>956 032100</phone>
      <email>sebastianf.garzon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexia Suárez Cabrera, Dr</last_name>
      <phone>928 450486</phone>
      <email>asuacab@gobiernodecanarias.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Escalante Barrigón, Dr</last_name>
      <phone>987 237400</phone>
      <email>fescalanteb@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio García Guiñón, Dr</last_name>
      <phone>973 705351</phone>
      <email>agarciag.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefa Nájera Irazu, Dr</last_name>
      <phone>941 298000</phone>
      <email>mjnajera@riojasalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Lavilla Rubia, Dr</last_name>
      <phone>982 296000</phone>
      <email>Esperanza.Lavilla.Rubira@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de octubre</name>
      <address>
        <city>MAdrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jose Lahuerta, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Martínez Martínez, Dr</last_name>
      <phone>91 3303321</phone>
      <email>rafaelbenigno.martinez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Jesús Blanchard Rodríguez, Dr</last_name>
      <phone>91 3368053</phone>
      <email>mjesusblanchard@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan José Lahuerta Palacios, Dr</last_name>
      <phone>91 3908000</phone>
      <email>jjlahuerta@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrián Alegre Amor, Dr</last_name>
      <phone>91 5202316</phone>
      <email>adrian.alegre@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Prieto Pareja, Dr</last_name>
      <phone>91 5504800</phone>
      <email>EPrieto@fjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ángel Hernández Rivas, Dr</last_name>
      <phone>91 1918932</phone>
      <email>jahernandezr@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana López de la Guía, Dr</last_name>
      <phone>91 7277116</phone>
      <email>lopguia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Pérez de Oteyza, Dr</last_name>
      <phone>91 7567863</phone>
      <email>jperezoteyza@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HU Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Encinas Rodríguez</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Encinas Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Joan de Deu (Althaia)</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Cabezudo, Dr</last_name>
      <phone>620992400</phone>
      <email>mcabezudo@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentin Cabañas Perianes, Dr</last_name>
      <phone>968 369532</phone>
      <email>valentin.cabanas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe de Arriba de la Fuente, Dr</last_name>
      <phone>968 360951</phone>
      <email>farriba@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Santa Lucía</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Romera Martínez, Dr</last_name>
      <phone>968 128600</phone>
      <email>marta.paramita@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Casanova Espinosa, Dr</last_name>
      <phone>951 976798</phone>
      <email>mariacasanova@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricarda García, Dr</last_name>
      <phone>951 032000</phone>
      <email>ricarda_g@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Angel Méndez Sánchez, Dr</last_name>
      <phone>988 3885500</phone>
      <email>Jose.Angel.Mendez.Sanchez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Ramírez Payer, Dr</last_name>
      <phone>985 108000</phone>
      <email>apayer.angel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Palencia</name>
      <address>
        <city>Palencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mª Alonso, Dr</last_name>
      <phone>979 167000</phone>
      <email>jalonsoa@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bargay Lleonart, Dr</last_name>
      <phone>871 202000</phone>
      <email>jbargay@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Sampol Mayol, Dr</last_name>
      <phone>971 175000</phone>
      <email>antonia.sampolm@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus San Miguel, Dr</last_name>
      <phone>948 296296</phone>
      <email>sanmiguel@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mª Arguiñano Pérez, Dr</last_name>
      <phone>848 429119</phone>
      <email>jm.arguinano.perez@cfnavarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana María Dios Loureiro, Dr</last_name>
      <phone>986 800050</phone>
      <email>ana.maria.dios.loureiro@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell (Parc Taulí)</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Rámila Herrero, Dr</last_name>
      <phone>937 231010</phone>
      <email>MRamila@tauli.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Victoria Mateos, Dr</last_name>
      <phone>923 291384</phone>
      <email>mvmateos@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maialen Sirvent Auzmendi, Dr</last_name>
      <phone>943 007000</phone>
      <email>MAIALEN.SIRVENTAUZMENDI@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Nuestra Señora de la Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Ríos, Dr</last_name>
      <phone>Pablo</phone>
      <email>pablo.riosrull@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Martín, Dr</last_name>
      <phone>942 315321</phone>
      <email>guillermo.martin@scsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Sonia González Pérez, Dr</last_name>
      <phone>981 950 171</phone>
      <email>marta.sonia.gonzalez.perez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aránzazu García Mateos, Dr</last_name>
      <phone>921 419671</phone>
      <email>aranzazugarciamateo@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Universitario Virgen de Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estrella Carrillo, Dr</last_name>
      <phone>955 013277</phone>
      <email>estrellacarrillocruz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señona de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Sarrá Escarré, Dr</last_name>
      <phone>977 295800</phone>
      <email>jsarra@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Teodoro Hernández García, Dr</last_name>
      <phone>922 678650</phone>
      <email>mthernan@ull.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo (Virgen de la Salud)</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Casado Montero, Dr</last_name>
      <phone>925 269243</phone>
      <email>lfcasadom@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Isabel Teruel Casasus, Dr</last_name>
      <phone>961 973838</phone>
      <email>ateruelc@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Arnao Herraiz, Dr</last_name>
      <phone>96 1244192</phone>
      <email>arnao_mar@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset Aleixandre</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de la Rubia, Dr</last_name>
      <phone>963 862500</phone>
      <email>delarubia_jav@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Margarita Martínez, Dr</last_name>
      <phone>986 217832</phone>
      <email>ana.margarita.martinez.castro@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Perez Persona, Dr</last_name>
      <phone>945 007171</phone>
      <email>ernesto.perezpersona@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Palomera Bernal, Dr</last_name>
      <phone>976 765700</phone>
      <email>lpalomera@salud.aragon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Delgado Beltrán, Dr</last_name>
      <phone>976 765500</phone>
      <email>pdelgadob@salud.aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

